The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Ultomiris (ravulizumab)
Australian Public Assessment Report
Device/Product Name
Ultomiris
Active ingredients
Ravulizumab
AusPAR Date
Published
Submission Number
PM-2023-02695-1-1
Submission Type
Extension of indication
Decision
Approved